Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
22.86B
Market cap22.86B
Price-Earnings ratio
14.46
Price-Earnings ratio14.46
Dividend yield
—
Dividend yield—
Average volume
1.76M
Average volume1.76M
High today
$113.75
High today$113.75
Low today
$110.08
Low today$110.08
Open price
$112.89
Open price$112.89
Volume
1.92M
Volume1.92M
52 Week high
$132.60
52 Week high$132.60
52 Week low
$82.82
52 Week low$82.82

Stock Snapshot

With a market cap of 22.86B, Incyte(INCY) trades at $112.75. The stock has a price-to-earnings ratio of 14.46.

During the trading session on 2026-10-08, Incyte(INCY) shares reached a daily high of $113.75 and a low of $110.08. At a current price of $112.75, the stock is +2.4% higher than the low and still -0.9% under the high.

Trading activity shows a volume of 1.92M, compared to an average daily volume of 1.76M.

The stock's 52-week range extends from a low of $82.82 to a high of $132.60.

The stock's 52-week range extends from a low of $82.82 to a high of $132.60.

INCY News

TipRanks 11h
Incyte price target raised to $114 from $109 at RBC Capital

RBC Capital raised the firm’s price target on Incyte (INCY) to $114 from $109 and keeps a Sector Perform rating on the shares as part of a broader research note...

Simply Wall St 1d
Incyte Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) moved back into focus for many investors after U.S. regulators cleared Atebrioz for fibrodysplasia ossificans progressiva, and partners reported e...

Incyte Won New Approvals, Is The Pullback A Cheap Entry?
Benzinga 1d
If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today - Benzinga

...

If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today - Benzinga

Analyst ratings

52%

of 31 ratings
Buy
41.9%
Hold
51.6%
Sell
6.5%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.